Betaferon sales likely to boost Schering's growth

Article Abstract:

Analysts said that Schering AG should see a growth in sales of its core Betaferon product in 1999. This should help the company's financial performance for the year. Betaferon is a drug treatment for multiple sclerosis. Schering's sales in 1998 struggled because of disadvantageous currency rates. The company said that its yearly group sales increased 2.9% to 6.4 billion marks ($3.68 billion).

Comment:

Analysts say co's 1999 performance should be helped by expected Betaferon sales

Germany, Forecasts, trends, outlooks, Abstract, Schering AG

Novo Nordisk's net beats expectations with a 54% jump

Article Abstract:

Novo Nordisk AS posted a higher-than-expected increase of 54% in its net profits for the 2000 year. The company posted 3.09 billion Danish kroner (414 million euros) in net profits for the year.

Novo Nordisk A/S

Danske Bank's net profit falls

Article Abstract:

Danske Bank A.S posted a drop of 5.4% in its net profits for the 2002 year. The bank posted 8.24 billion Danish kroner (1.11 billion euros) in net profits for the year.

Banking industry, Company sales and earnings, Company earnings/profit, Danske Bank A/S